State of the Biopharmaceutical Industry 2023

Accessing in-depth insights from the ‘State of the Biopharmaceutical Industry’ report will help you –

• Examine the current attitudes of business leaders towards the emerging trends impacting the biopharmaceutical industry in the next 12 months.
• Understand the most impactful emerging technologies – Industry, Regulatory and Macroeconomic factors that are going to impact and dominate the industry throughout 2023.
• Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023, highlight top-selling drugs (2022 vs 2023), and overview the clinical trials landscape for 2023.
• Uncover the healthcare industry professionals’ sentiment about the industry’s growth prospects during the next 12 months and how this sentiment changed over the past 3 years.

How is the ‘State of the Biopharmaceutical Industry’ report different from other reports in the market?

• It measures which themes are going to have the greatest positive or negative impact on the pharmaceutical industry in 2023.
• It provides a qualitative analysis of the top regions (Europe, North America, and APAC).
• It analyzes key emerging trends (regulatory and macroeconomic trends) as well as emerging technologies.
• The State of the Biopharmaceutical Industry report highlights the planned clinical trials, projected clinical trails completions, top-selling drugs, and drug launches that are going to happen in 2023.
• Understand other topics that GlobalData identified as important for you (Inflation Reduction Act, prospects of deflation, the rise of ESG, and reshoring of pharmaceutical manufacturing) and adjust your business development strategies.

 We recommend this valuable source of information to anyone involved in:

• Pharmaceutical Companies
• Biotech
• CMOs, CMOs, and CDMOs
• Consulting Companies
• Technology Companies and Start-ups
• Professional Services (e.g., Investment, Equity Companies, Banks)

To Get a Snapshot of the State of the Biopharmaceutical Industry Report, Download a Free Report Sample

State of the Biopharmaceutical Industry Report Overview

The pharmaceutical industry has long been labeled as recession-proof, as medicines are essential products that cannot be completely replaced. However, the looming global recession is likely to have implications on healthcare budgets, forcing governments and regulators to put more stringent laws in place around drug pricing and market access. At the same time, the pharmaceutical industry will have to deal with increased drug development costs that will affect their margins.

The state of the biopharmaceutical industry research report examines the business environment and trends that are going to shape the biopharmaceutical industry in 2023. The report highlights the most impactful emerging technologies, industry, regulatory, and macroeconomic factors that are going to impact and dominate the industry throughout 2023.

Key Findings of the Biopharmaceutical Industry

In 2023, businesses will face turbulent times, and the pharmaceutical industry is not an exception. Financial and costs pressures, as well as increasing regulations and an uncertain economic outlook will be contributing to decreased levels of optimism in growth prospects. To sustain growth, the pharmaceutical industry will need to innovate.

Furthermore, to remain competitive, businesses need to ensure integration, cost-effectiveness, efficiency, and customer excellence, as well as to attain innovative solutions and investor support. Vertical integration, patent expiry of biologics, mega M&As, and ESG factors are anticipated to have the greatest positive impact on the pharmaceutical industry. In addition, big data and AI will continue to dominate as transformational forces in the healthcare sector in 2023.

Emerging Industry Trends in the Biopharmaceutical Industry

The key emerging industry trends in the biopharmaceutical industry are genomics, immuno-oncology drug development, personalized/precision medicine, real-world evidence, remote patient monitoring, electronic health records, biosimilar uptake, decentralized/virtual clinical trials, digital therapeutics, and patient empowerment among others. Genomics is identified as the top emerging pharmaceutical industry trend for 2023.

Biopharmaceutical Industry Analysis, by Emerging Trends, 2023 (%)

For more emerging trend insights in the biopharmaceutical industry, download a free report sample

Emerging Technologies in the Biopharmaceutical Industry

The key emerging technologies impacting the biopharmaceutical industry are AI, big data, cybersecurity, digital media, social media, virtual and augmented reality, IoT, robotics, application programming interfaces, cloud computing, 3-D printing, and blockchain among others. Across all geographies, AI, followed by big data are expected to have the biggest impact on the pharmaceutical industry in 2023.

Biopharmaceutical Industry, by Emerging Technologies, 2023 (%)

For more emerging technology insights in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry Value Chain

The value chain of the biopharmaceutical industry includes supply chain, drug development, end-user experience, physician-targeted sales and marketing, drug discovery, manufacturing, and patient-targeted sales and marketing. Supply chain and manufacturing will be impacted the most by inflation in 2023.

Therapy Areas in the Biopharmaceutical Industry

The top therapy areas for planned clinical trials to be initiated in 2023 in the biopharmaceutical industry are oncology, central nervous system, infectious disease, cardiovascular, gastrointestinal, metabolic disorders, respiratory, immunology, musculoskeletal disorders, and dermatology. Oncology trials will outnumber CNS and infectious disease trials.

Biopharmaceutical Industry, by Therapy Areas (To be Initiated in 2023, %)

For more insights on the therapy areas in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry – Competitive Landscape

Top industry sponsors for trials projected to be completed in 2023 are AstraZeneca, Novartis, Johnson & Johnson (J&J), F Hoffman La Roche, Pfizer, Eli Lily, Merck, Abbvie, and GSK among others. AstraZeneca, Novartis, and Johnson & Johnson (J&J) will likely complete the most industry trials in 2023.

Biopharmaceutical Industry, by Industry Sponsors, 2023 (%)

For more industry sponsor insights in the biopharmaceutical industry, download a free report sample

Biopharmaceutical Industry Report Overview

Biopharmaceutical Industry Therapy Areas Outlook (2023)

• Oncology
• Central Nervous System
• Infectious Disease
• Cardiovascular
• Gastrointestinal
• Metabolic Disorders
• Respiratory
• Immunology
• Musculoskeletal Disorders
• Dermatology

Scope

This report provides:

• A snapshot of current attitudes of business leaders toward the emerging industry trends and how they are shaping the future of the healthcare industry
• Overview of the hindrances and drivers that will affect the state of the biopharmaceutical industry
• Emerging technologies that are expected to have the greatest impact on the biopharmaceutical industry in the next 12 months
• Executives’ opinions on the growth prospects of the biopharmaceutical industry over the next 12 months
• Key industry shake-ups and trends to watch that represent both challenges and opportunities to the industry

Reasons to Buy

• Stay up to date with the major emerging technologies and regulatory, macroeconomic, and industry trends that will impact the pharmaceutical industry in 2023.
• Explore how the biopharmaceutical landscape has changed
• Identify the most impactful anticipated regulatory approvals and drug launches in the industry in 2023
• Gain insight into the regulatory and microeconomics trends that will have positive and negative effects on the biopharmaceutical industry
• Identify emerging industry trends and innovations to gain a competitive advantage